# EDGAR Filing Document

**Accession Number:** 0001790340
**File Stem:** 0001104659-23-014535
**Filing Date:** 2023-2
**Character Count:** 8339
**Document Hash:** 26ac9b31a8ecae276a34975177547c9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-014535.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001104659-23-014535

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuneering Corp
- **CENTRAL INDEX KEY:** 0001790340
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92766
- **FILM NUMBER:** 23599266

**BUSINESS ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-500-8080

**MAIL ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeskind Benjamin J.
- **CENTRAL INDEX KEY:** 0001870062

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** C/O IMMUNEERING CORPORATION
- **STREET 2:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**Securities and Exchange Commission**

**Washington, D.C. 20549**

**Schedule 13G**

**(Rule 13d-102)**

**Information to be Included in Statements Filed Pursuant**

**to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed**

**Pursuant to § 240.13d-2**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

(Amendment No. 1)\*

**Immuneering Corporation**

(Name of Issuer)

**Class A Common Stock**

(Title of Class of Securities)

**45254E107**

(CUSIP Number)

**December 31, 2022**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b)

◻ Rule 13d-1(c)

⌧ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45254E107 <u>Schedule 13G</u> <u>Page 1 of 4</u>

---

| | | |
|:---|:---|:---|
| 1 | Names of Reporting Persons<br>**Benjamin J. Zeskind** | Names of Reporting Persons<br>**Benjamin J. Zeskind** |
| 2 | Check the Appropriate Box if a Member of a Group | (a) ◻<br> (b) ◻ |
| 3 | SEC Use Only | SEC Use Only |
| 4 | Citizenship or Place of Organization<br>**United States** | Citizenship or Place of Organization<br>**United States** |

---

---

| | | |
|:---|:---|:---|
| Number of Shares<br> Beneficially Owned<br> by Each Reporting<br> Person With | 5 | &nbsp;&nbsp;&nbsp; Sole Voting Power<br>**2,600,859** |
| Number of Shares<br> Beneficially Owned<br> by Each Reporting<br> Person With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shared Voting Power<br>**894,927** |
| Number of Shares<br> Beneficially Owned<br> by Each Reporting<br> Person With | 7 | &nbsp;&nbsp;&nbsp; Sole Dispositive Power<br>**2,600,859** |
| Number of Shares<br> Beneficially Owned<br> by Each Reporting<br> Person With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shared Dispositive Power<br>**894,927** |

---

---

| | |
|:---|:---|
| 9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggregate Amount Beneficially Owned by Each Reporting Person<br>**3,495,786** |
| 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>**Not Applicable** |
| 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Percent of Class Represented by Amount in Row 9<br>**13.1%** |
| 12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type of Reporting Person<br>**IN** |

---

CUSIP No. 45254E107 <u>Schedule 13G</u> <u>Page 2 of 4</u>

---

| | | |
|:---|:---|:---|
| **ITEM 1.** | **(a)** | **Name of Issuer:** |

---

Immuneering Corporation (the "Issuer").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Address of Issuer's Principal Executive Offices:** 

245 Main St., Second Floor, Cambridge, MA 02142

---

| | | |
|:---|:---|:---|
| **ITEM 2.** | **(a)** | **Name of Person Filing:** |

---

This statement is filed on behalf of Benjamin J. Zeskind (the "Reporting Person").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Address or Principal Business Office:** 

The principal business address of the Reporting Person is c/o Immuneering Corporation, 245 Main St., Second Floor, Cambridge, MA 02142.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** **Citizenship of each Reporting Person is:** 

The Reporting Person is a citizen of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** **Title of Class of Securities:** 

Class A common stock, par value $0.001 per share ("Class A Common Stock").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** **CUSIP Number:** 

45254E107

**ITEM** **3.**

Not applicable.

---

| | |
|:---|:---|
| **ITEM 4.** | **Ownership.** |

---

**(a-c)**

The ownership information presented below represents beneficial ownership of the shares of Class A Common Stock of the Issuer as of December 31, 2022, based upon 26,404,732 shares of Class A Common Stock outstanding as of November 3, 2022, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.

CUSIP No. 45254E107 <u>Schedule 13G</u> <u>Page 3 of 4</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | &nbsp;&nbsp;**Amount<br> beneficially<br> owned** | &nbsp;&nbsp;**Percent<br> of class:** | &nbsp;&nbsp;**Sole power<br> to vote or to<br> direct the<br> vote:** | &nbsp;&nbsp;**Shared power<br> to vote or to<br> direct the vote:** | &nbsp;&nbsp;**Sole<br> power to<br> dispose or<br> to direct<br> the<br> disposition<br> of:** | &nbsp;&nbsp;**Shared<br> power to<br> dispose or<br> to direct<br> the<br> disposition<br> of:** |
| Benjamin J. Zeskind | &nbsp;&nbsp;3495786 | &nbsp;&nbsp;13.1% | &nbsp;&nbsp;2600859 | &nbsp;&nbsp;894927 | &nbsp;&nbsp;2600859 | &nbsp;&nbsp;894927 |

---

The Reporting Person is the beneficial owner of 3,495,786 shares of Class A Common Stock, which consist of (i) 2,261,852 shares of Class A Common Stock held of record by the Reporting Person; (ii) 339,007 shares of Class A Common Stock underlying stock options held of record by the Reporting Person that are exercisable on or prior to March 1, 2023; and (iii) 894,927 shares of Class A Common Stock held of record by the Benjamin J. Zeskind 2020 Family Trust, of which the Reporting Person's spouse serves as sole trustee.

---

| | |
|:---|:---|
| **ITEM 5.** | **Ownership of Five Percent or Less of a Class.** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 6.** | **Ownership of More than Five Percent on Behalf of Another Person.** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 7.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 8.** | **Identification and Classification of Members of the Group.** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 9.** | **Notice of Dissolution of Group.** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 10.** | **Certification.** |

---

Not applicable.

CUSIP No. 45254E107 <u>Schedule 13G</u> <u>Page 4 of 4</u>

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Date**: February 8, 2023

---

| |
|:---|
| **Benjamin J. Zeskind** |
| /s/ Benjamin J. Zeskind |

---